Deep search
Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
Order byBest matchMost fresh
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
18d

Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to ...

Detailed price information for Maze Therapeutics Inc (MAZE-Q) from The Globe and Mail including charting and trades.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Trending now

To pay $24.5M to end suit
GSK CEO to step down
Says Israel agreed to US plan
Sentenced to 7 yrs in prison
Accused of eating peacocks
Enters GA governor’s race
On Tomahawk for Ukraine
First Brands bankruptcy
Mourns death of his dog
Was denied Singapore entry
Oregon sues Trump admin
Dutch cargo ship damaged
To shed 4,000 jobs by 2030
US govt. shutdown looms
Hangs alleged spy for Israel
Lola Young cancels show
To be acquired in $55B deal
To sell stake in solar assets
Postpones Las Vegas shows
Kansas officer fatally shot
Iowa revokes license
Moldova’s pro-EU party wins
Getting parental controls
Renounces her US visa
Bans civilian drone flights
Expand delivery partnership
Internet blackout hits AFG
Giants fire veteran manager
Airlines warn of slowdown
To miss Wild Card Series
CSX appoints new CEO
Mulls AL Senate campaign
Enters WI governor race
Madagascar protests
Feedback
  • Privacy
  • Terms